ECTRIMS 2024 – Late Breaking Oral Presentations.

This document provides a summary of various studies and trials related to multiple sclerosis (MS). The studies investigate different aspects of MS, including the association between changes in serum glial fibrillary acidic protein (sGFAP) and neurofilament light chain (sNfL) levels with long-term progression independent of relapse activity (PIRA) risk, the relationship between depression and disease activity and disability worsening in individuals with MS, the immune response to the Epstein-Barr virus (EBV) in MS patients, and the effectiveness of simvastatin in slowing disability progression in secondary progressive MS. The document also discusses ongoing trials evaluating the efficacy and safety of tolebrutinib in participants with relapsing MS and non-relapsing secondary progressive MS. The results of these studies and trials will contribute to a better understanding of MS and potential treatment options. [Extracted from the article]